Subthreshold Diode Laser Versus Trabeculotomy in Treatment of Advanced Primary Open Angle Glaucoma

May 9, 2026 updated by: Mohamed Mahmoud Refaat Elahmady, Kafrelsheikh University
This study aimed to compare between subthreshold diode laser and trabeculotomy in treatment of advanced primary open angle glaucoma throughout 12 months follow-up.

Study Overview

Detailed Description

Glaucoma is a common eye disease that can cause irreversible blindness if left undiagnosed and untreated. Glaucoma is caused by elevated intraocular pressure (IOP) that leads to optic nerve damage and visual field loss.

Trabeculectomy operation was first described more than 50 years ago and is considered the most commonly performed surgery worldwide for glaucoma patients.

Subthreshold transscleral cyclophotocoagulation is a micropulse delivery mode of diode laser that has been used recently to treat glaucoma by ablating the ciliary processes and reducing the aqueous humour production.

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Kafrelsheikh
      • Kafr ash Shaykh, Kafrelsheikh, Egypt, 33516
        • Kafrelsheikh University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients older than 18 years.
  • Open angle glaucoma.
  • Advanced glaucoma (visual field deterioration MD>-12.00 dB with evidence of optic neuropathy despite maximal therapy).

Exclusion Criteria:

  • Previous intraocular surgery for glaucoma.
  • Patients who had undergone previous laser therapy for glaucoma.
  • Cases of secondary glaucoma.
  • Media opacity interferes with capturing fundus image.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group A
Patients scheduled for subthreshold diode laser.
Patients scheduled for subthreshold diode laser.
Experimental: Group B
Patients scheduled for trabeculotomy.
Patients scheduled for trabeculotomy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Visual acuity
Time Frame: 12 months postoperatively
Visual acuity was evaluated using finger counting, hand motion, or light perception
12 months postoperatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intraocular pressure
Time Frame: 12 months postoperatively
Intraocular pressure was measured and success criteria included an IOP ranging from 6 to 21 mmHg or a minimum 20% decline from baseline, with or without antiglaucoma drugs.
12 months postoperatively
Degree of pain
Time Frame: 12 months postoperatively
Postoperative pain was assessed using a visual analogue scale from 0 to 10 cm: 0-4 cm for mild, 5-7 cm for moderate, and 8-10 cm for intense pain.
12 months postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2024

Primary Completion (Actual)

December 1, 2024

Study Completion (Actual)

December 1, 2024

Study Registration Dates

First Submitted

May 9, 2026

First Submitted That Met QC Criteria

May 9, 2026

First Posted (Actual)

May 18, 2026

Study Record Updates

Last Update Posted (Actual)

May 18, 2026

Last Update Submitted That Met QC Criteria

May 9, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • MD.22.12.724

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

IPD Sharing Time Frame

After the end of study for one year.

IPD Sharing Access Criteria

The data will be available upon a reasonable request from the corresponding author.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe